Author - Stephen Kilmer


BTIG cuts Senseonics to neutral from buy; removes PT

BTIG downgraded Senseonics Holdings (NYSE American:SENS) to “neutral” from “buy” and removed its price target, citing Senseonics’ stock price, which has soared about 500% over the past month. The stock closed at $2.67...


HCW ups XOMA PT to $56 from $30

H.C. Wainwright raised its price target for XOMA (NASDAQ:XOMA) to $56 from $30, citing the company’s growing asset base, which is linked to both increasing levels of milestone payments and future royalty potential from...


SVB Leerink ups NextGen Healthcare PT to $21 from $14

SVB Leerink raised its price target for NextGen Healthcare (NASDAQ:NXGN) to $21 from $14, citing unaudited preliminary fiscal third quarter results ended Dec. 31, 2020 that beat Street estimates and higher fiscal 2021...

Stifel starts Neoleukin Therapeutics at buy; PT $18

Stifel launched coverage of Neoleukin Therapeutics (NASDAQ:NLTX) with a “buy” rating and $18 price target. The stock closed at $14.61 on Jan. 5. Neoleukin is creating next generation immunotherapies primarily for...


HCW starts Kazia Therapeutics at buy; PT $17

H.C. Wainwright launched coverage of Kazia Therapeutics (NASDAQ:KZIA) with a “buy” rating and price target of $17. The stock closed at $8.98 on Jan. 4. Kazia is developing novel therapies against brain cancer. Its lead...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.